| 摘要 |
The invention concerns methods of treating malignant gliomas, by administering inhibitors of TGF-beta the TGF-beta signaling pathway, including molecules preferably binding to the type I TGF-beta receptor (TGFbeta-R1). Preferably, the inhibitors are non-peptide small molecules, including quinazoline derivatives. The invention also concerns methods for reversing the TGF-beta-mediated effect on glioma cells to make them less refractile to signaling and other immune cells, comprising contacting a glioma cell or tissue in vivo or in vitro, with an inhibitor of TGF-beta.
|
